AQST
Live chart
What they do
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis.
For information only · Important disclosures
Grades vs sector
No sector grades for AQST yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.49 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-0.57 vs trailing $-0.66. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 2/9 · last two fiscal years
Altman Z-score -3.4 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $44.5M | $-83.8M | $-53.0M |
| 2024 | $57.6M | $-44.1M | $-35.9M |
| 2023 | $50.6M | $-7.9M | $-7.4M |
| 2022 | $47.7M | $-54.4M | $-10.8M |
| 2021 | $50.8M | $-70.5M | $-33.9M |
| 2020 | $45.8M | $-55.8M | $-46.0M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -2.2%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-11 | -0.12 | -0.07 | +45.7% |
| 2026-05-13 | -0.13 | -0.05 | +64.7% |
| 2026-03-04 | -0.12 | -0.14 | -18.1% |
| 2025-11-05 | -0.11 | -0.11 | -4.2% |
| 2025-08-11 | -0.17 | -0.12 | +32.3% |
| 2025-05-12 | -0.16 | -0.22 | -39.7% |
| 2025-03-05 | -0.13 | -0.16 | -21.3% |
| 2024-11-04 | -0.12 | -0.11 | +7.2% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $13.8M | +38.1% |
| 2026-03-31 | $14.4M | – |
| 2025-12-31 | $13.0M | – |
| 2025-09-30 | $12.8M | – |
| 2025-06-30 | $10.0M | – |
Analyst actions
PT $10
PT $8
PT $12
PT $8
PT $10
PT $10
Stats refreshed 2026-10-21 01:31:49 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026